Robert Wittenberg (@PharmerRob) header
Robert Wittenberg (@PharmerRob) profile picture

Robert Wittenberg

@PharmerRob

Advertising, Promotion, & Labeling; Social Media in Pharma/Device World. Policy Wonk. FDA OPDP (né DDMAC), APLB, CDRH Office of Compliance DPLC, HEOR

 Chicagoland
Joined April 2009
  • Tweets4.2K
  • Following565
  • Followers465
Amgen Says US FDA’s Advertising Warning Letter Was For The Wrong Promotional Video insights.citeline.com/pink-s…
Amgen Says US FDA’s Advertising Warning Letter Was For The Wrong Promotional Video

Amgen Says US FDA’s Advertising Warning Letter Was For The Wrong Promotional Video

The FDA issued a warning letter for a video about Amgen’s Vectibix because it did not include any risk information, but Amgen said it sent the wrong version of the video for review.

insights.citeline.com
34
Amgen hit with FDA warning letter for ‘misleading’ Vectibix promotion fiercepharma.com/marketing/a…
Amgen hit with FDA warning letter for ‘misleading’ Vectibix promotion

Amgen hit with FDA warning letter for ‘misleading’ Vectibix promotion

Amgen has been handed an FDA warning letter over a video promoting its cancer drug Vectibix, but the company said the issues stemmed from an inadvertent submission and was not made available public |...

fiercepharma.com
1
2
162
Prevalence of ties to industry-funded organizations among patient and consumer representatives on FDA advisory committees academic.oup.com/healthaffai…
Prevalence of ties to industry-funded organizations among patient and consumer representatives on...

Prevalence of ties to industry-funded organizations among patient and consumer representatives on...

AbstractIntroduction. FDA advisory committees are primarily composed of scientific experts, but also include a patient representative and a consumer repres

academic.oup.com
1
37
Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds statnews.com/pharmalot/2026/… via @statnews
Pharma's free lunches for doctors boost inappropriate prescribing, analysis finds

Pharma's free lunches for doctors boost inappropriate prescribing, analysis finds

The gifts and payments that doctors receive from drugmakers increased inappropriate prescribing, likely leading to rising health care costs, according to a new review.

statnews.com
30
The gifts from pharma companies that keep on giving statnews.com/pharmalot/2026/… via @statnews
The gifts from pharma companies that keep on giving

The gifts from pharma companies that keep on giving

There has been rancorous debate over doctors accepting free gifts and speaking fees from pharma companies. That doesn't mean doctors have reconsidered.

statnews.com
73
FDA is urged by advocacy group to ban DTC prescription drug ads statnews.com/pharmalot/2026/… via @statnews
FDA is urged by advocacy group to ban DTC prescription drug ads

FDA is urged by advocacy group to ban DTC prescription drug ads

A leading advocacy group petitioned the FDA to ban direct-to-consumer advertising of prescription medicines.

statnews.com
31
FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV fiercepharma.com/marketing/f…
FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV

FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, taking issue with the company’s characterization of the med as a general |...

fiercepharma.com
49
One last #OPDP publication? FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing Presence, Prominence, and Wording link.springer.com/article/10…
FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing...

FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing...

Therapeutic Innovation & Regulatory Science - The US Food and Drug Administration (FDA) provides a pathway, known as accelerated approval, intended to facilitate and expedite development and...

link.springer.com
34
US FDA Moves To Eliminate ‘Adequate Provision’ For DTC Broadcast Ads insights.citeline.com/pink-s…
US FDA Moves To Eliminate ‘Adequate Provision’ For DTC Broadcast Ads

US FDA Moves To Eliminate ‘Adequate Provision’ For DTC Broadcast Ads

The proposed rule targeted for December would force drugmakers to include all important risk information in an ad, a change the agency predicted will cost industry more than $100m annually.

insights.citeline.com
49
PI Episode 5: FDA's New Proposed Rule Will Create a Veritable "Ban" on ... youtu.be/ZlmFAccYYEw?si=1ZHv… via @YouTube
Why is FDA Calling Adequate Provision a "LOOPHOLE"? [PI Episode 5]

Why is FDA Calling Adequate Provision a "LOOPHOLE"? [PI Episode 5]

The FDA's latest proposal targets what they refer to as the "adequa...

youtube.com
1
105
Recent US FDA Ad/Promo Untitled Letters Citing More Email, Internet Issues, Less DTC TV Spots insights.citeline.com/pink-s…
Recent US FDA Ad/Promo Untitled Letters Citing More Email, Internet Issues, Less DTC TV Spots

Recent US FDA Ad/Promo Untitled Letters Citing More Email, Internet Issues, Less DTC TV Spots

Recent Office of Prescription Drug Promotion violation notices cite emails directed at healthcare providers, a YouTube video and consumer websites.

insights.citeline.com
30
FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails fiercepharma.com/marketing/f…
FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails

FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails

The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug. | The FDA has...

fiercepharma.com
34
BeOne Medicines’ Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions' fiercepharma.com/marketing/b…
BeOne Medicines’ Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions'

BeOne Medicines’ Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions'

The FDA has issued an untitled letter to BeOne Medicines’ U.S. | The FDA has issued an untitled letter to BeOne Medicines’ U.S. subsidiary over a TV commercial promoting its BTK blood cancer drug...

fiercepharma.com
55
Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive fiercepharma.com/marketing/i…
Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive

Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive

Insulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels.  | Insulet has always been a...

fiercepharma.com
45
Alnylam rebuked by FDA over efficacy claims on Amvuttra website fiercepharma.com/marketing/a…
Alnylam rebuked by FDA over efficacy claims on Amvuttra website

Alnylam rebuked by FDA over efficacy claims on Amvuttra website

The FDA has hit (PDF) Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech | The FDA has hit Alnylam with an untitled letter over the consumer website for...

fiercepharma.com
70
Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals' fiercepharma.com/marketing/b…
Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals'

Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals'

The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s prostate cancer drug Nubeqa.  | The FDA has reprimanded Bayer for the “atten...

fiercepharma.com
26
From Former # OPDP Researchers: Clinicians’ Reactions to Point-of-Care Advertising in Electronic Health Records link.springer.com/article/10…

Clinicians’ Reactions to Point-of-Care Advertising in Electronic Health Records

Therapeutic Innovation & Regulatory Science - Pharmaceutical marketers have introduced novel ways to deliver point-of-care advertising to clinicians through their electronic health record...

link.springer.com
46
AMA calls for regulatory crackdown on chatbots, wellness AI statnews.com/2026/04/23/ama-… via @statnews
AMA calls for regulatory crackdown on chatbots, wellness AI

AMA calls for regulatory crackdown on chatbots, wellness AI

In this edition of STAT Health Tech: OpenAI's targets clinicians, AMA's call for regulatory crackdown, and bargain-basement telehealth visits.

statnews.com
42
Drug ads face new scrutiny at FDA and on Hill axios.com/2026/04/20/drug-ad…
Drug ads face new scrutiny at FDA and on Hill

Drug ads face new scrutiny at FDA and on Hill

The U.S. and New Zealand are the only countries that allow direct-to-consumer pharmaceutical advertising.

axios.com
51
Pfizer rebuked by FDA for misleading Adcetris ads on Facebook fiercepharma.com/marketing/p…
Pfizer rebuked by FDA for misleading Adcetris ads on Facebook

Pfizer rebuked by FDA for misleading Adcetris ads on Facebook

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately communicate the indication, contraindications and risks. | The FDA has...

fiercepharma.com
1
38
Load more